Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Functional genomics study on Non Alcoholic fatty liver disease (NAFLD) - part II (Study ST000679)

C18 NEGATIVE ION MODE (Analysis AN001044)

Metabolite	Structure	F1	F2	F3	F4	F5	F6	F7	F8
CerP 34:0; [M-H]-@6.05	ME188601	0.72	0.60	0.35	0.59	0.70	0.57	0.25	4.21
PA 34:1; [M-H]-@5.80	ME188634	0.29	0.62	0.26	0.19	0.96	0.32	1.64	3.73
PS 40:6; [M-H]-@5.98	ME188823	0.62	2.50	2.07	0.31	0.78	0.32	1.11	0.29
plasmenyl-PE 34:2; [M-H]-@6.71	ME188828	0.90	0.32	0.64	0.26	0.48	1.84	1.06	2.50
N-(docosanoyl)-sphinganine; [M-H]-@8.63	ME188622	0.25	0.56	0.28	1.53	2.43	0.67	0.73	1.54
PC 28:0; [M-Ac-H]-@5.18	ME188636	0.22	0.58	0.51	1.84	2.55	0.46	0.73	1.10
PI 40:7; [M-H]-@5.38	ME188808	0.37	0.45	0.46	1.82	2.64	0.46	0.71	1.09
CL 64:4; [M-2H](2-)@8.72	ME188578	0.19	0.93	0.46	1.48	3.04	0.70	0.60	0.61
CL 72:6; [M-2H](2-)@9.37	ME188595	0.46	0.59	0.73	1.55	2.85	0.39	0.80	0.63
lysoPE 22:5; [M-H]-@1.56	ME188825	0.52	0.56	0.90	2.17	1.80	0.80	0.67	0.60
plasmenyl-PE 40:6; [M-H]-@7.20	ME188839	0.43	0.56	0.89	1.76	2.15	0.70	0.68	0.82
PI 38:5; [M-H]-@5.46	ME188802	0.38	1.15	0.93	1.53	1.90	0.42	1.34	0.36
CL 74:11; [M-2H](2-)@5.63	ME188596	0.43	0.53	0.75	1.29	2.31	0.52	1.06	1.11
PE 36:6; [M-H]-@5.53	ME188725	0.41	0.57	0.74	1.26	2.27	0.54	1.22	0.99
CL 68:5; [M-2H](2-)@9.04	ME188585	0.36	1.15	0.85	1.27	2.17	0.51	0.97	0.72
plasmenyl-PE 42:6; [M-H]-@7.72	ME188841	0.38	0.92	0.95	1.31	2.06	0.61	1.02	0.74
PE 39:6; [M-H]-@6.57	ME188739	0.67	0.81	0.89	0.89	2.19	0.63	0.97	0.95
PE 40:7; [M-H]-@6.40	ME188742	0.70	0.79	1.15	1.15	2.15	0.64	0.82	0.60
PG 30:0; [M-H]-@5.24	ME188755	0.44	0.64	1.16	0.41	1.58	1.02	1.09	1.66
PC 36:5; [M-Ac-H]-@5.72	ME188664	0.79	0.44	0.81	1.03	2.01	0.72	0.71	1.48
PS 34:2; [M-H]-@5.43	ME188811	0.26	0.64	0.66	1.53	1.84	0.53	0.99	1.56
N-(eicosanoyl)-sphinganine; [M-H]-@8.16	ME188624	0.27	1.03	0.37	1.02	2.22	0.52	0.98	1.59
N-(octadecanoyl)-sphinganine; [M-H]-@7.65	ME188628	0.23	0.74	0.39	1.26	2.16	0.79	0.96	1.48
PC 26:0; [M-Ac-H]-@4.45	ME188635	0.52	0.77	0.78	0.85	1.76	0.75	1.02	1.54
PC 30:0; [M-Ac-H]-@5.90	ME188638	0.32	0.83	0.66	1.19	1.81	0.78	1.10	1.31
PC 30:1; [M-Ac-H]-@5.39	ME188639	0.35	0.79	0.62	1.12	1.63	0.62	1.05	1.83
CL 70:7; [M-2H](2-)@5.87	ME188591	0.52	0.86	0.82	0.79	1.33	0.62	1.26	1.80
PE 32:1; [M-H]-@6.20	ME188716	0.52	0.84	0.78	1.10	1.28	0.72	1.07	1.69
CL 66:4; [M-2H](2-)@9.00	ME188580	0.27	1.38	0.69	1.12	1.62	0.58	1.25	1.09
PS 32:1; [M-H]-@5.29	ME188809	0.29	1.32	0.81	0.76	1.53	0.80	1.13	1.37
N-(eicosanoyl)-sphing-4-enine; [M-H]-@7.99	ME188623	0.36	1.37	0.54	0.73	1.39	0.83	1.22	1.55
PC 29:0; [M-Ac-H]-@5.49	ME188637	0.32	1.21	0.69	0.68	1.42	0.78	1.41	1.50
PC 42:8; [M-Ac-H]-@6.45	ME188701	0.81	0.99	0.60	1.36	1.28	0.86	1.00	1.11
PE 40:2; [M-H]-@7.94	ME188740	0.71	1.28	1.18	0.95	1.46	0.61	0.94	0.88
PI 36:1; [M-H]-@6.43	ME188795	0.74	1.11	1.03	1.10	1.62	0.56	0.72	1.13
lysoPE 24:1; [M-H]-@4.42	ME188826	0.48	0.93	1.20	1.76	0.90	0.39	1.36	0.99
PC 40:8; [M-Ac-H]-@5.77	ME188690	0.47	1.51	0.87	1.25	1.32	0.58	1.38	0.61
PI 34:2; [M-H]-@5.30	ME188794	0.56	1.26	1.01	1.09	1.24	0.53	1.37	0.94
PI 36:2; [M-H]-@5.93	ME188796	0.33	1.24	1.00	1.36	1.24	0.47	1.54	0.80
PI 34:1; [M-H]-@5.82	ME188793	0.43	1.82	1.52	1.01	1.37	0.34	1.12	0.40
PI 38:6; [M-H]-@5.17	ME188803	0.36	1.60	1.09	0.97	1.64	0.47	1.36	0.51
PS 40:7; [M-H]-@5.44	ME188824	0.40	1.76	0.91	1.07	1.52	0.69	1.18	0.48
PC 30:2; [M-Ac-H]-@4.93	ME188640	0.79	0.76	0.83	0.54	0.63	0.49	0.79	3.17
PE 34:3; [M-H]-@6.01	ME188721	0.49	0.79	0.71	0.42	0.61	0.90	1.46	2.63
CL 66:5; [M-2H](2-)@5.47	ME188581	0.70	0.55	0.94	0.53	0.73	0.56	1.23	2.75
PC 32:3; [M-Ac-H]-@5.29	ME188646	0.69	0.71	1.00	0.26	0.46	0.63	1.32	2.93
CL 66:3; [M-2H](2-)@6.03	ME188579	0.63	0.48	1.00	0.66	1.27	0.57	0.85	2.54
PE 32:2; [M-H]-@5.98	ME188717	0.57	0.62	0.95	0.69	1.08	0.73	0.98	2.38
CL 70:2; [M-2H](2-)@5.95	ME188586	0.30	0.64	0.56	0.73	1.18	0.94	1.10	2.56
PG 32:0; [M-H]-@5.91	ME188756	0.64	0.56	0.59	1.07	1.16	0.86	0.77	2.36
N-(hexadecanoyl)-sphing-4-enine; [M-H]-@6.82	ME188625	0.80	1.19	0.68	0.38	0.83	1.12	0.91	2.09
CL 74:3; [M-2H](2-)@6.22	ME188597	0.69	0.96	0.71	0.76	0.77	0.98	1.16	1.95
N-(tetradecanoyl)-sphing-4-enine; [M-H]-@6.22	ME188631	0.51	1.16	0.61	0.53	0.90	1.10	1.33	1.86
PC 44:4; [M-Ac-H]-@8.30	ME188708	0.82	0.67	0.76	0.41	0.79	1.17	1.03	2.35
PE 31:1; [M-H]-@5.95	ME188715	0.76	0.79	1.17	0.19	0.68	0.77	1.30	2.35
CL 70:5; [M-2H](2-)@6.14	ME188589	0.78	0.79	1.01	0.41	0.68	0.86	1.31	2.17
PC 36:3; [M-Ac-H]-@6.43	ME188662	0.83	0.85	0.80	0.46	0.80	0.86	1.36	2.04
N-(hexadecanoyl)-sphinganine; [M-H]-@7.08	ME188626	0.65	0.92	0.56	0.82	0.91	0.60	1.00	2.55
N-(tetradecanoyl)-sphinganine; [M-H]-@6.45	ME188632	0.55	1.14	0.82	0.53	0.85	0.61	1.08	2.43
PC 32:2; [M-Ac-H]-@5.63	ME188645	0.51	0.94	0.83	0.56	0.77	0.74	1.38	2.28
PE 37:0; [M-H]-@7.98	ME188726	0.55	1.10	0.72	0.60	0.88	0.58	1.47	2.11
PC 36:6; [M-Ac-H]-@5.38	ME188665	1.29	0.69	1.08	0.57	1.56	0.87	0.81	1.14
PC 38:5; [M-Ac-H]-@6.31	ME188674	1.60	0.78	1.05	0.54	1.11	0.98	0.84	1.09
PC 42:7; [M-Ac-H]-@6.79	ME188700	1.74	0.83	1.00	0.74	1.07	0.82	0.78	1.02
PC 40:5; [M-Ac-H]-@6.94	ME188687	1.94	0.83	0.94	0.37	0.74	0.89	0.79	1.51
PC 42:9; [M-Ac-H]-@6.14	ME188702	1.65	1.02	1.24	0.32	0.79	0.83	1.17	0.98
PE 40:8; [M-H]-@5.98	ME188743	1.46	0.70	1.34	0.37	0.72	0.83	1.09	1.51
PC 40:6; [M-Ac-H]-@6.58	ME188688	1.28	1.05	0.83	0.59	0.82	0.92	1.22	1.29
PC 38:4; [M-Ac-H]-@6.65	ME188673	1.61	0.85	0.99	0.37	0.63	0.88	1.27	1.40
PC 42:6; [M-Ac-H]-@7.13	ME188699	1.59	1.06	0.87	0.36	0.58	0.87	1.16	1.51
PC 39:1; [M-Ac-H]-@8.06	ME188677	1.03	1.32	0.84	0.35	0.81	0.99	0.97	1.69
PC 39:5; [M-Ac-H]-@6.63	ME188680	1.22	1.16	0.98	0.37	0.80	0.85	0.95	1.67
PC 40:2; [M-Ac-H]-@7.83	ME188684	1.08	1.11	0.98	0.45	0.73	1.08	0.96	1.60
PC 42:5; [M-Ac-H]-@7.37	ME188698	1.30	0.78	0.83	0.53	0.69	0.95	0.98	1.94
FFA(20:0)	ME188606	0.90	0.86	1.07	0.64	0.88	0.78	0.94	1.93
FFA(22:0)	ME188610	0.85	0.88	1.05	0.63	0.93	0.79	0.96	1.91
PC 46:4; [M-Ac-H]-@8.70	ME188711	1.23	1.11	1.03	0.17	0.09	0.93	1.67	1.77
PC 39:3; [M-Ac-H]-@7.34	ME188678	1.11	1.24	0.88	0.17	0.38	0.89	1.60	1.72
PC 39:4; [M-Ac-H]-@7.08	ME188679	1.06	1.22	0.86	0.26	0.36	0.96	1.72	1.57
PC 44:6; [M-Ac-H]-@7.58	ME188710	1.09	0.88	0.62	0.35	0.46	1.30	1.50	1.81
plasmenyl-PE 34:1; [M-H]-@7.16	ME188827	1.28	0.60	0.63	0.27	0.58	1.44	1.43	1.77
PC 44:5; [M-Ac-H]-@7.94	ME188709	0.82	1.07	0.80	0.27	0.50	1.21	1.45	1.87
PC 40:3; [M-Ac-H]-@7.50	ME188685	0.96	1.08	0.71	0.44	0.61	1.06	1.30	1.84
PC 42:4; [M-Ac-H]-@7.73	ME188697	0.84	1.23	0.79	0.35	0.56	0.98	1.34	1.91
PC 46:6; [M-Ac-H]-@7.99	ME188713	1.24	0.98	0.82	0.30	0.44	1.08	1.15	1.99
PC 38:3; [M-Ac-H]-@7.02	ME188672	1.21	0.97	0.83	0.33	0.50	0.96	1.43	1.77
PC 40:4; [M-Ac-H]-@7.24	ME188686	1.11	1.00	0.79	0.43	0.57	0.96	1.39	1.76
PC 46:5; [M-Ac-H]-@8.32	ME188712	1.53	1.11	0.87	0.13	0.25	1.19	1.14	1.78
PC 34:3; [M-Ac-H]-@5.86	ME188652	1.28	0.64	1.17	0.27	0.37	0.84	1.17	2.26
N-(17Z-hexacosenoyl)-sphing-4-enine; [M-H]-@8.92	ME188620	1.38	0.88	0.90	0.39	0.31	0.78	1.30	2.05
PC 37:3; [M-Ac-H]-@6.83	ME188667	1.30	1.07	0.95	0.11	0.36	0.85	1.28	2.07
N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.45	ME188627	0.67	1.12	0.75	0.57	1.24	1.48	0.82	1.35
CL 72:3; [M-2H](2-)@7.55	ME188592	0.89	0.58	0.89	0.87	0.67	1.26	1.33	1.52
PG 44:9; [M-H]-@5.68	ME188792	0.94	1.01	0.74	0.58	0.78	1.43	1.22	1.31
PG 34:3; [M-H]-@4.74	ME188762	0.37	1.62	1.88	0.09	0.21	0.80	1.62	1.40
PC 43:1; [M-Ac-H]-@9.02	ME188703	0.56	1.92	1.22	0.06	0.10	1.07	1.87	1.20
PI 37:3; [M-H]-@6.04	ME188799	0.47	2.26	1.13	0.18	0.23	0.65	2.16	0.93
PG 35:3; [M-H]-@5.08	ME188765	0.46	2.14	0.90	0.08	0.29	0.77	2.03	1.32
PS 39:3; [M-H]-@6.65	ME188820	0.46	2.07	1.11	0.17	0.30	0.71	1.87	1.31
PC 33:0; [M-Ac-H]-@6.74	ME188647	0.61	1.52	1.15	0.25	0.55	1.00	1.79	1.14
plasmenyl-PE 38:4; [M-H]-@7.21	ME188835	0.69	1.27	1.15	0.37	0.61	1.08	1.74	1.10
PS 36:3; [M-H]-@5.82	ME188814	0.49	1.54	1.05	0.61	0.48	0.75	2.02	1.06
PE 35:1; [M-H]-@7.03	ME188722	0.38	1.56	1.26	0.34	0.53	0.80	1.95	1.17
PE 37:2; [M-H]-@7.24	ME188728	0.51	1.60	1.27	0.30	0.45	0.78	1.93	1.16
PG 39:6; [M-H]-@5.30	ME188777	0.37	1.88	0.97	0.18	0.40	1.14	2.07	0.98
PG 35:2; [M-H]-@5.45	ME188764	0.22	1.88	1.08	0.30	0.42	0.84	2.02	1.24
PG 36:3; [M-H]-@5.36	ME188768	0.22	1.68	0.95	0.33	0.46	0.99	1.96	1.41
PS 40:4; [M-H]-@6.52	ME188822	0.58	2.02	0.81	0.52	0.45	0.79	1.77	1.06
PG 35:1; [M-H]-@6.27	ME188763	0.40	1.69	0.77	0.52	0.66	0.85	2.18	0.93
PG 36:1; [M-H]-@6.56	ME188766	0.39	1.71	0.85	0.29	0.51	0.79	2.29	1.18
PI 36:3; [M-H]-@5.75	ME188797	0.50	1.81	0.99	0.46	0.56	0.52	2.09	1.07
PI 40:3; [M-H]-@6.87	ME188804	0.71	1.53	0.87	0.63	0.68	0.50	2.02	1.06
PG 40:5; [M-H]-@5.94	ME188779	0.51	1.81	0.70	0.13	0.25	1.14	1.74	1.71
PG 33:2; [M-H]-@4.82	ME188759	0.30	1.60	1.12	0.15	0.32	0.82	1.95	1.74
PG 36:4; [M-H]-@5.03	ME188769	0.28	1.65	0.99	0.22	0.32	0.98	1.79	1.78
PG 38:3; [M-H]-@5.91	ME188772	0.44	1.73	1.10	0.25	0.43	1.29	1.34	1.42
PE 44:1; [M-H]-@9.21	ME188751	0.49	1.76	1.26	0.06	0.30	1.09	1.51	1.52
PG 38:5; [M-H]-@5.32	ME188774	0.42	1.83	1.05	0.27	0.32	1.10	1.67	1.34
PG 42:7; [M-H]-@5.81	ME188786	0.79	1.74	0.78	0.26	0.41	1.12	1.64	1.25
PG 42:5; [M-H]-@6.35	ME188784	0.71	1.80	0.85	0.31	0.37	0.70	1.59	1.67
PG 42:6; [M-H]-@6.08	ME188785	0.82	1.70	0.84	0.24	0.37	0.94	1.47	1.61
PS 38:3; [M-H]-@6.39	ME188816	0.80	1.02	0.86	0.53	0.73	0.77	1.93	1.36
PC 38:1; [M-Ac-H]-@7.75	ME188670	0.78	1.14	0.92	0.51	0.74	0.83	1.69	1.38
PE 38:4; [M-H]-@6.73	ME188733	0.61	1.09	0.97	0.52	0.89	0.84	1.67	1.42
PE 33:0; [M-H]-@6.91	ME188718	0.39	1.41	0.78	0.45	0.73	0.76	1.72	1.77
PE 31:0; [M-H]-@6.29	ME188714	0.46	1.15	0.90	0.45	0.92	0.69	1.53	1.90
PE 41:4; [M-H]-@7.73	ME188744	0.53	1.26	0.91	0.44	0.91	0.84	1.52	1.60
N-(docosanoyl)-sphing-4-enine; [M-H]-@8.48	ME188621	0.59	1.42	0.77	0.58	0.78	0.81	1.29	1.75
PE 40:4; [M-H]-@7.47	ME188741	0.66	1.20	0.88	0.56	0.68	0.83	1.47	1.72
N-(15Z-tetracosenoyl)-sphinganine; [M-H]-@8.65	ME188619	0.87	1.27	0.86	0.41	0.64	0.93	1.46	1.58
N-(tetracosanoyl)-sphing-4-enine; [M-H]-@8.92	ME188629	0.87	1.27	0.86	0.41	0.64	0.93	1.46	1.58
FFA(24:0)	ME188614	0.57	1.64	0.88	0.35	0.64	0.73	1.24	1.96
PC 41:2; [M-Ac-H]-@8.10	ME188692	0.63	1.35	0.87	0.27	0.66	0.98	1.42	1.82
PC 44:3; [M-Ac-H]-@8.47	ME188707	0.58	1.39	0.94	0.24	0.35	1.26	1.52	1.73
PC 35:4; [M-Ac-H]-@5.83	ME188658	0.63	1.39	0.78	0.24	0.50	1.05	1.55	1.86
PC 42:3; [M-Ac-H]-@7.95	ME188696	0.67	1.36	0.82	0.24	0.40	1.10	1.68	1.73
PG 32:2; [M-H]-@4.80	ME188758	0.26	1.59	1.06	0.27	0.59	1.01	1.42	1.79
PC 31:0; [M-Ac-H]-@6.15	ME188641	0.53	1.28	1.13	0.25	0.78	1.15	1.37	1.51
PE 42:4; [M-H]-@7.93	ME188747	0.41	1.38	1.07	0.46	0.72	0.99	1.36	1.62
PG 38:4; [M-H]-@6.07	ME188773	0.51	1.22	0.95	0.32	0.50	0.50	2.07	1.93
PE 37:1; [M-H]-@7.57	ME188727	0.40	1.33	1.14	0.18	0.40	0.91	2.12	1.53
CL 80:5; [M-2H](2-)@7.30	ME188600	0.58	1.21	1.02	0.14	0.34	0.83	2.17	1.70
PC 37:1; [M-Ac-H]-@7.41	ME188666	0.67	1.24	1.05	0.25	0.30	0.87	2.09	1.53
plasmenyl-PE 38:3; [M-H]-@7.59	ME188834	0.58	1.30	0.92	0.08	0.15	1.12	2.26	1.59
PE 37:3; [M-H]-@7.00	ME188729	0.52	1.50	0.86	0.19	0.38	1.04	2.08	1.44
PS 39:4; [M-H]-@6.30	ME188821	0.50	1.52	1.00	0.15	0.24	1.09	2.14	1.37
PE 33:2; [M-H]-@5.99	ME188720	0.42	1.30	1.13	0.25	0.61	1.08	1.81	1.40
PE 35:4; [M-H]-@5.99	ME188723	0.44	1.24	0.95	0.20	0.54	1.03	1.95	1.65
PE 37:4; [M-H]-@6.64	ME188730	0.56	1.40	1.06	0.23	0.48	0.89	2.03	1.36
PC 33:1; [M-Ac-H]-@6.29	ME188648	0.43	1.50	1.01	0.26	0.57	0.81	1.96	1.46
PE 39:2; [M-H]-@7.69	ME188736	0.54	1.46	1.11	0.29	0.56	0.70	1.85	1.50
CL 70:4; [M-2H](2-)@9.49	ME188588	0.56	1.31	1.08	0.48	0.62	0.84	1.81	1.31
PE 33:1; [M-H]-@6.49	ME188719	0.42	1.37	1.03	0.38	0.76	0.75	1.81	1.49
PC 42:1; [M-Ac-H]-@8.69	ME188693	0.75	1.58	1.08	0.07	0.26	0.96	1.80	1.48
PC 37:4; [M-Ac-H]-@6.47	ME188668	0.92	1.26	0.91	0.19	0.43	0.96	1.90	1.43
PC 40:1; [M-Ac-H]-@8.22	ME188683	0.79	1.23	0.88	0.37	0.54	1.04	1.78	1.38
PC 36:1; [M-Ac-H]-@7.19	ME188660	0.71	1.25	1.00	0.35	0.54	0.86	1.72	1.59
PC 41:1; [M-Ac-H]-@8.34	ME188691	0.76	1.26	1.06	0.31	0.47	0.75	1.69	1.70
PC 35:1; [M-Ac-H]-@7.01	ME188655	0.68	1.38	1.12	0.30	0.41	0.86	1.69	1.56
PC 43:2; [M-Ac-H]-@8.48	ME188704	0.66	1.43	1.11	0.23	0.37	0.94	1.81	1.44
plasmenyl-PE 34:3; [M-H]-@6.54	ME188829	0.67	0.99	0.75	0.28	0.22	1.09	2.25	1.74
PC 44:1; [M-Ac-H]-@9.14	ME188705	0.69	0.99	1.14	0.17	0.33	1.20	1.82	1.65
PC 35:3; [M-Ac-H]-@6.26	ME188657	0.65	1.07	0.87	0.30	0.58	0.88	1.75	1.90
PC 44:2; [M-Ac-H]-@8.73	ME188706	0.67	0.79	1.02	0.36	0.48	1.13	1.67	1.88
FFA(22:3)	ME188613	1.20	1.53	1.37	0.09	0.10	1.03	1.33	1.34
PG 36:5; [M-H]-@4.76	ME188770	0.59	1.47	1.46	0.10	0.24	1.03	1.44	1.68
PC 35:2; [M-Ac-H]-@6.47	ME188656	0.79	1.27	1.37	0.23	0.44	1.04	1.49	1.36
PE 44:3; [M-H]-@8.69	ME188752	0.87	1.30	1.45	0.24	0.41	1.25	1.38	1.10
plasmenyl-PE 38:1; [M-H]-@8.20	ME188833	0.92	1.13	1.18	0.42	0.44	0.99	1.40	1.53
PE 39:3; [M-H]-@7.52	ME188737	0.89	1.24	1.22	0.09	0.29	0.94	1.58	1.74
PC 42:2; [M-Ac-H]-@8.30	ME188695	0.95	1.23	1.19	0.19	0.34	1.09	1.31	1.70
plasmenyl-PE 40:3; [M-H]-@8.10	ME188838	0.99	1.36	1.37	0.11	0.32	0.99	1.36	1.50
PE 44:4; [M-H]-@8.50	ME188753	0.44	1.76	1.40	0.27	0.61	0.90	1.49	1.13
PC 36:0; [M-Ac-H]-@7.69	ME188659	0.31	1.62	1.20	0.46	0.68	0.93	1.51	1.30
PC 31:1; [M-Ac-H]-@5.67	ME188642	0.51	1.45	1.21	0.54	0.77	0.80	1.46	1.25
PE 42:3; [M-H]-@8.25	ME188746	0.51	1.55	1.13	0.50	0.74	0.87	1.47	1.23
PG 34:2; [M-H]-@5.29	ME188761	0.18	1.71	0.95	0.73	0.69	1.09	1.41	1.23
PG 38:2; [M-H]-@6.30	ME188771	0.35	1.76	1.11	0.45	0.86	1.15	1.29	1.03
PC 39:6; [M-Ac-H]-@6.31	ME188681	1.11	1.27	1.06	0.40	0.58	1.02	1.60	0.97
PC 39:7; [M-Ac-H]-@5.91	ME188682	1.07	1.40	1.11	0.61	0.60	0.94	1.30	0.97
PE 39:4; [M-H]-@7.14	ME188738	0.97	1.47	1.40	0.19	0.46	0.82	1.66	1.03
FFA(22:2)	ME188612	0.90	1.73	1.35	0.20	0.29	0.90	1.44	1.20
FFA(24:1)	ME188615	0.73	1.77	1.29	0.31	0.47	0.80	1.47	1.17
FFA(18:2)	ME188605	0.78	1.53	1.30	0.23	0.32	0.84	1.69	1.30
FFA(20:2)	ME188608	0.88	1.48	1.45	0.29	0.34	0.82	1.45	1.28
FFA(20:1)	ME188607	0.80	1.60	1.30	0.56	0.66	0.85	1.44	0.80
FFA(22:1)	ME188611	0.75	1.74	1.33	0.42	0.57	0.84	1.42	0.93
CL 68:4; [M-2H](2-)@9.26	ME188584	0.70	1.68	1.24	0.37	0.82	0.81	1.19	1.20
PE 46:4; [M-H]-@8.83	ME188754	0.95	1.53	1.21	0.28	0.64	0.81	1.37	1.21
PI 38:4; [M-H]-@5.89	ME188801	0.83	1.58	1.77	0.53	1.20	0.51	1.07	0.51
PC 37:5; [M-Ac-H]-@6.04	ME188669	1.04	1.04	1.66	0.40	0.92	0.78	1.17	0.99
PE 42:9; [M-H]-@6.29	ME188750	1.01	1.10	1.54	0.27	0.57	0.90	1.72	0.89
plasmenyl-PE 36:4; [M-H]-@6.67	ME188831	0.73	1.31	1.63	0.47	0.68	1.13	1.42	0.63
PA 32:1; [M-H]-@6.06	ME188633	0.66	0.88	0.57	0.46	0.82	0.96	2.37	1.29
N-(tetracosanoyl)-sphinganine; [M-H]-@9.07	ME188630	0.35	1.20	0.56	0.49	0.92	0.80	1.95	1.73
PG 32:1; [M-H]-@5.25	ME188757	0.33	0.89	0.59	0.85	1.15	1.02	1.72	1.45
PS 38:5; [M-H]-@5.60	ME188818	0.62	0.99	1.18	0.79	0.73	0.74	2.12	0.83
PG 36:2; [M-H]-@5.99	ME188767	0.19	1.48	0.79	0.79	0.82	1.34	1.73	0.87
CL 68:2; [M-2H](2-)@9.63	ME188582	0.48	1.13	0.80	0.74	1.14	1.29	1.78	0.62
PS 38:6; [M-H]-@5.37	ME188819	0.46	1.40	1.01	0.65	1.19	0.93	1.82	0.54
PC 33:2; [M-Ac-H]-@5.92	ME188649	0.79	1.09	1.15	0.69	0.71	0.74	1.31	1.52
CL 78:5; [M-2H](2-)@6.91	ME188599	0.61	0.99	1.04	0.69	0.96	0.73	1.43	1.55
PC 38:2; [M-Ac-H]-@7.29	ME188671	0.81	1.03	0.87	0.68	0.86	0.83	1.44	1.50
PC 32:1; [M-Ac-H]-@6.00	ME188644	0.43	1.06	0.80	0.66	1.07	0.85	1.45	1.67
PC 34:2; [M-Ac-H]-@6.29	ME188651	0.55	0.98	0.87	0.68	0.97	0.79	1.44	1.71
FFA(18:0)	ME188603	0.54	0.93	0.74	0.97	0.95	0.78	1.30	1.79
PC 36:2; [M-Ac-H]-@6.75	ME188661	0.56	0.92	0.83	1.00	1.08	0.82	1.28	1.51
FFA(16:0)	ME188602	0.57	1.03	0.80	0.90	0.93	0.82	1.33	1.62
PE 42:6; [M-H]-@7.24	ME188748	0.58	1.02	0.93	0.83	1.00	0.81	1.23	1.61
N-(15Z-tetracosenoyl)-sphing-4-enine; [M-H]-@8.43	ME188618	0.94	0.88	0.91	0.57	1.15	1.00	1.06	1.50
PC 35:0; [M-Ac-H]-@7.32	ME188654	0.69	0.82	0.88	0.75	1.25	1.01	1.14	1.46
PE 38:6; [M-H]-@6.12	ME188734	0.71	0.80	0.92	0.61	1.16	1.01	1.34	1.44
PC 36:4; [M-Ac-H]-@6.11	ME188663	0.95	1.00	0.84	0.54	1.11	0.84	1.33	1.40
PC 38:7; [M-Ac-H]-@5.58	ME188676	0.99	0.92	0.85	0.71	1.15	0.82	1.36	1.20
PC 34:4; [M-Ac-H]-@5.49	ME188653	1.09	0.98	1.14	0.58	1.04	0.59	1.16	1.42
PE 42:8; [M-H]-@6.61	ME188749	0.94	1.04	1.01	0.76	1.02	0.64	1.29	1.29
PI 40:5; [M-H]-@6.13	ME188806	0.66	1.26	0.92	0.94	0.98	0.78	1.56	0.91
PS 36:1; [M-H]-@6.56	ME188812	0.38	1.27	0.95	0.93	1.19	0.72	1.63	0.92
PS 36:2; [M-H]-@6.02	ME188813	0.40	1.42	1.01	0.76	0.86	0.64	1.94	0.97
CL 68:3; [M-2H](2-)@9.45	ME188583	0.46	1.44	0.92	0.70	0.74	0.79	1.72	1.22
CL 70:3; [M-2H](2-)@9.68	ME188587	0.55	1.26	1.00	0.63	0.84	0.90	1.75	1.07
PS 36:4; [M-H]-@5.44	ME188815	0.47	1.31	0.93	0.66	1.03	0.92	1.68	1.01
PC 34:1; [M-Ac-H]-@6.59	ME188650	0.69	1.09	1.09	0.81	1.20	0.80	1.15	1.16
PE 38:0; [M-H]-@7.88	ME188731	0.53	1.21	1.08	0.82	1.08	0.71	1.36	1.21
PE 38:1; [M-H]-@7.87	ME188732	0.66	1.22	1.31	0.73	1.01	0.66	1.30	1.12
plasmenyl-PE 36:5; [M-H]-@6.24	ME188832	0.73	0.97	1.31	0.67	0.78	1.08	1.25	1.21
PC 32:0; [M-Ac-H]-@6.50	ME188643	0.56	0.92	0.93	0.75	1.08	0.98	1.44	1.33
plasmenyl-PE 36:0; [M-H]-@7.70	ME188830	0.49	0.93	0.98	0.67	1.13	1.08	1.53	1.20
CL 72:4; [M-2H](2-)@9.70	ME188593	0.69	1.06	1.02	0.80	0.83	1.12	1.45	1.03
FFA(18:1)	ME188604	0.59	1.27	0.96	0.74	0.89	0.99	1.46	1.09
PE 36:0; [M-H]-@7.83	ME188724	0.60	1.18	0.88	0.61	0.96	1.08	1.54	1.15
PS 34:1; [M-H]-@5.94	ME188810	0.46	1.71	1.48	0.49	0.89	0.63	1.66	0.69
PI 36:4; [M-H]-@5.36	ME188798	0.47	1.69	1.19	0.61	1.04	0.69	1.63	0.67
PI 40:4; [M-H]-@6.37	ME188805	0.55	1.77	1.04	0.70	0.90	0.69	1.62	0.73
PI 40:6; [M-H]-@5.89	ME188807	0.64	1.14	0.97	0.87	1.49	0.64	1.57	0.68
PE 39:1; [M-H]-@8.03	ME188735	0.63	1.32	1.06	0.57	1.21	0.61	1.64	0.96
PE 41:6; [M-H]-@7.07	ME188745	0.61	1.33	1.06	0.50	1.42	0.58	1.56	0.94
CL 74:6; [M-2H](2-)@9.59	ME188598	0.76	1.20	1.15	0.79	1.23	0.69	1.48	0.69
CL 70:5; [M-2H](2-)@9.32	ME188590	0.68	1.40	1.12	0.76	1.17	0.64	1.49	0.74
CL 72:5; [M-2H](2-)@9.55	ME188594	0.77	1.34	1.25	0.77	1.02	0.66	1.48	0.71
PC 42:10; [M-Ac-H]-@5.69	ME188694	0.96	1.43	1.24	0.59	1.07	0.55	1.21	0.94
plasmenyl-PE 42:5; [M-H]-@7.99	ME188840	0.60	1.55	1.40	0.56	1.10	0.87	1.15	0.76
PC 38:6; [M-Ac-H]-@6.02	ME188675	0.99	0.99	0.94	0.68	1.15	0.93	1.41	0.90
PC 40:7; [M-Ac-H]-@6.19	ME188689	1.29	1.17	1.20	0.63	0.93	0.81	1.30	0.67
plasmenyl-PE 38:5; [M-H]-@7.02	ME188836	0.87	0.98	1.39	0.75	1.42	0.94	0.93	0.72
FFA(20:4) Arachidonic acid	ME188609	0.66	1.00	1.34	0.72	1.07	1.16	1.33	0.72
plasmenyl-PE 38:6; [M-H]-@6.61	ME188837	0.42	1.06	1.28	1.04	1.27	0.86	1.43	0.63
PG 44:11; [M-H]-@5.02	ME188790	1.06	1.39	1.34	0.06	0.41	2.25	1.06	0.42
PG 34:1; [M-H]-@5.83	ME188760	0.89	0.92	0.88	0.35	0.89	1.82	1.38	0.88
PG 44:10; [M-H]-@5.43	ME188789	1.01	1.32	0.77	0.09	0.44	1.84	1.76	0.78
PG 40:6; [M-H]-@5.56	ME188780	0.48	1.82	0.91	0.29	0.62	1.41	1.63	0.85
PG 38:6; [M-H]-@5.00	ME188775	0.54	1.50	1.33	0.10	0.43	1.62	1.43	1.04
PG 42:9; [M-H]-@5.02	ME188788	1.08	1.32	1.36	0.06	0.35	1.61	1.24	0.97
PG 42:10; [M-H]-@4.76	ME188783	0.90	1.34	1.59	0.15	0.19	1.53	1.52	0.79
PG 42:8; [M-H]-@5.36	ME188787	0.83	1.60	1.33	0.12	0.41	1.36	1.61	0.74
PG 40:7; [M-H]-@5.18	ME188781	0.35	1.30	1.13	0.22	0.59	1.91	1.82	0.66
PG 38:7; [M-H]-@4.55	ME188776	0.43	1.17	1.55	0.07	0.34	1.75	1.99	0.71
PG 40:8; [M-H]-@4.79	ME188782	0.47	1.36	1.27	0.06	0.29	1.56	2.04	0.95
PI 38:3; [M-H]-@6.35	ME188800	0.78	2.14	1.50	0.25	0.49	0.46	1.74	0.63
FFA(24:3)	ME188617	0.87	2.39	1.32	0.15	0.25	0.92	1.30	0.81
FFA(24:2)	ME188616	0.81	2.19	1.17	0.12	0.20	1.15	1.56	0.81
PG 44:8; [M-H]-@5.95	ME188791	0.75	2.06	1.06	0.18	0.24	1.02	1.74	0.95
PG 39:7; [M-H]-@4.90	ME188778	0.44	1.77	1.45	0.22	0.29	1.28	2.12	0.43
PS 38:4; [M-H]-@6.00	ME188817	0.57	1.60	1.65	0.20	0.31	0.69	2.67	0.31

Factors:

F1	Construct:GCKR_52621
F2	Construct:NT-25-9-16
F3	Construct:PNPLA3_50053
F4	Construct:PNPLA3(I148M)
F5	Construct:PNPLA3(WT)
F6	Construct:PPP1R3B_2640-25-9-16
F7	Construct:TM6SF2_382426
F8	Construct:Vector-25-9-16

Data matrix